Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation

Trial Profile

Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Neurofibromatosis 2
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Dec 2016 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 02 Dec 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top